Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2019
December 2019, Vol 10, No 6
December 2019, Vol 10, No 6
Brukinsa Receives Accelerated FDA Approval for Mantle-Cell Lymphoma
FDA Approvals, News & Updates
December 2019, Vol 10, No 6
On November 14, 2019, the FDA granted accelerated approval to zanubrutinib capsules (Brukinsa; BeiGene), a Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of adults with mantle-cell lymphoma who have received at least 1 previous therapy.
Read Article
Postsurgery Observation Better Than Radiotherapy in Men with Prostate Cancer
ESMO 2019
December 2019, Vol 10, No 6
Barcelona, Spain—Results of the new clinical trial RADICALS-RT indicate that using salvage radiotherapy immediately after surgery leads to equivalent outcomes in terms of progression-free survival (PFS) versus adjuvant radiotherapy in men with prostate cancer undergoing radical prostatectomy.
Read Article
Targeted Therapy with Olaparib Beneficial in Metastatic Prostate Cancer with Gene Mutations
By
Phoebe Starr
ESMO 2019
December 2019, Vol 10, No 6
Barcelona, Spain—The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza) delayed disease progression and showed a trend toward improved survival compared with newer hormonal agents in men with pretreated metastatic castrate-resistant prostate cancer (CRPC) and homologous recombinant repair (
HRR
) gene mutations or with
BRCA1
,
BRCA2
, and
ATM
mutations. Results of this late-breaker were reported at the ESMO Congress 2019 during the presidential session.
Read Article
Ceritinib Effective in Treating Brain Metastases in NSCLC
By
Phoebe Starr
ESMO 2019
December 2019, Vol 10, No 6
Barcelona, Spain—Treatment with ceritinib (Zykadia) led to excellent responses in patients with
ALK
-positive non–small-cell lung cancer (NSCLC) and brain metastases, according to results of the ASCEND-7 clinical trial, which enrolled only patients with
ALK
-positive NSCLC with newly diagnosed or progressive brain metastases.
Read Article
Selecting Treatment for Relapsed/Refractory Multiple Myeloma in the Era of Multiple Choices
By
Meg Barbor, MPH
NCCN 2019 Hematologic Malignancies
December 2019, Vol 10, No 6
San Francisco, CA—Keeping up with the many treatment advances in relapsed or refractory multiple myeloma can be a challenge for even the most informed providers, according to Jorge J. Castillo, MD, Clinical Director, Bing Center for Waldenström’s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Read Article
Steroids plus Exercise Reduce Fatigue in Patients with Advanced Cancer
By
Corbin Davis
Supportive Care 2019 Symposium
December 2019, Vol 10, No 6
San Francisco, CA—Steroids plus exercise could be the best combination for treating fatigue in patients with advanced cancer, according to data presented at the 2019 Supportive Care in Oncology Symposium.
Read Article
Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer
By
Phoebe Starr
ESMO 2019
December 2019, Vol 10, No 6
Barcelona, Spain—Poly (ADP-ribose) polymerase (PARP) inhibition has an established role as maintenance therapy in women with newly diagnosed high-grade advanced ovarian cancer and a
BRCA
mutation. At the ESMO Congress 2019, results of 3 clinical trials expand the use of PARP inhibition in ovarian cancer to all patients.
Read Article
Real-World Applications of Value-Based Care in Oncology
AVBCC 2019 Summit
December 2019, Vol 10, No 6
New York, NY—With cancer drugs representing some of the most expensive pharmaceuticals on the market, conversations abound around value in oncology and proposed solutions for achieving it. At the 2019 AVBCC Summit, experts on the topic of drug pricing hashed out which frameworks are best suited for real-world applications in cancer care.
Read Article
Page 3 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma